CC DEADLINE: SueWallSt Reminds The Chemours Company Investors of Upcoming Securities Class Action Deadline

Key Dates and Disclosure Events Shareholders Need to Know. The complaint traces how Chemours allegedly reaffirmed its 2026 outlook from February through May while an oversupplied Opteon aftermarket channel was allegedly eroding the demand behind it.

NEW YORK, Oct. 22, 2026 /PRNewswire/ -- SueWallSt reminds purchasers of The Chemours Company (NYSE: CC) securities of a pending class action on behalf of investors who bought between February 20, 2026 and August 4, 2026 and suffered losses. YOUR OPTIONS: You may be entitled to compensation without payment of any out-of-pocket fees. See if you could be eligible to recover, or contact Joseph E. Levi, Esq. at [email protected] or (888) SueWallSt.

Chemours timeline of disclosure events, in brief: On February 20, 2026, Chemours guided to 2026 adjusted EBITDA of $800 million to $900 million. On August 4, 2026, it cut that range to $775 million to $825 million, and by the August 5 close CC shares had fallen $3.34, or 18.63%, to $14.59. Investors have until December 7, 2026 to seek lead plaintiff status.

February 20 to May 7, 2026: Confidence Restated as Warning Signs Multiplied

The lawsuit chronicles a Class Period that opened with a record fourth quarter for Opteon refrigerants, growth that management tied to AIM Act adoption, and stated confidence in the full-year guide. On May 5, Chemours posted $1.4 billion in first-quarter net sales with record TSS results and reaffirmed its outlook, citing higher TSS demand.

Two days later, management acknowledged that about $10 million of adjusted EBITDA impact had been pulled forward into the first quarter, yet held the forecast and described a strong aftermarket position. It is alleged that aftermarket demand was already decreasing during this stretch because Opteon products had been oversold in 2025.

August 4 and 5, 2026: The Outlook Resets

After the August 4 close, Chemours reported second-quarter net sales of $1.6 billion, down about 1%, on a 4% volume decline it attributed to lower Opteon aftermarket sales against elevated 2025 demand from the initial channel fill. On the next morning's call, management described an oversupplied channel heading into 2026 and pointed to customer prebuying in 2025. As set forth in the complaint, these disclosures corrected prior alleged misstatements about demand and guidance.

"Timely disclosure of material developments is fundamental to fair and efficient markets. The complaint alleges that Chemours held its full-year outlook in May even after noting demand pulled into the first quarter, and investors deserve to know whether the risks described in August were apparent sooner." -- Joseph E. Levi, Esq.

Measuring the Chemours Timeline: Disclosure Events in Days

• 74 days separated the February 20 outlook from its May 5 reaffirmation, a span in which the complaint alleges aftermarket demand was already declining.
• 2 days passed between that reaffirmation and the call that flagged a first-quarter demand pull-forward.
• 91 days elapsed between the May 5 reaffirmation and the August 4 guidance cut.
• One trading session separated the after-hours August 4 release from the August 5 repricing.
• 65 days after the cut, on October 8, 2026, the complaint was filed in the U.S. District Court for the District of Delaware.

Calculate your potential recovery or call (888) SueWallSt.

WHY SUEWALLST: SueWallSt is powered by Levi & Korsinsky LLP. Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States.

Frequently Asked Questions About the CC Lawsuit

Q: What specific misstatements does the CC lawsuit allege? A: The complaint alleges The Chemours Company made materially false or misleading statements regarding aftermarket demand for its Opteon refrigerant products and the reliability of its 2026 financial guidance during the Class Period. When a reduced full-year adjusted EBITDA outlook and an oversupplied Opteon aftermarket channel were disclosed, the stock price declined sharply.

Q: When did The Chemours Company allegedly mislead investors? A: The Class Period runs from February 20, 2026 to August 4, 2026. The complaint alleges that corrective disclosures revealed information that caused a significant stock decline.

Q: What court was the CC class action filed in? A: The case was filed in the United States District Court for the District of Delaware, governed by the Private Securities Litigation Reform Act of 1995.

Q: What is a lead plaintiff and why does it matter? A: A lead plaintiff is the investor appointed by the court to represent the entire class. Lead plaintiffs are typically investors with the largest documented losses. Being appointed does not increase individual recovery but gives direct oversight of how the case is run.

Q: What if I already sold my CC shares -- can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought during the Class Period and sold at a loss may still be eligible to participate.

Q: How long will the lawsuit take to resolve? A: Securities class actions typically take two to four years from initial filing to resolution. Timing depends on the court schedule, case developments, and whether the matter is dismissed, settled, or litigated further.

Q: Do I need to go to court or give testimony? A: No. The overwhelming majority of class members never appear in court or give depositions. If there is a settlement or recovery, eligible class members generally submit a claim form to seek their portion.

CONTACT:

Levi & Korsinsky, LLP

Joseph E. Levi, Esq.

33 Whitehall Street, 27th Floor

New York, NY 10004

[email protected]

Tel: (888) SueWallSt

Fax: (212) 363-7171

Attorney Advertising. Prior results do not guarantee similar outcomes.

SOURCE SueWallSt.com